About us

We are the official representative in Lithuania of the leading international company (Germany, UK, US, India) DATAR CANCER GENETICS actively working in the oncology field. We are the first in the country to offer individualized, comprehensive, and reliable tests from a blood sample (liquid biopsy), which allow to determine the circulating tumor cells (CTC’s) in the body and the genetic and other specific characteristics of a solid tumor.

The purple ribbon, a universally recognized symbol for all types of cancer, was chosen as the trademark. The purple ribbon symbolizes solidarity, and at the same time reminds us of the infinity sign, which in this case means the infinity of information obtained from molecular research. It also reminds us of the flow of life, the constant change without beginning and end, where the supposed end always leads to the beginning of a new cycle.

Vision

The innovative solutions developed by our partners are very important in the treatment of advanced oncological disease, tumors that are more difficult to treat, such as breast, prostate, intestine, etc. The particular tests also help in the early detection of cancerous diseases, and this largely determines the success of the treatment of these diseases. A lot of important information is hidden in the blood, the obtained results are analyzed with the help of artificial intelligence, and this helps to optimize or adjust the treatment.

Values

The tests are focused on cancer prevention, diagnosis and treatment selection based on scientific and clinical evidence. During the validation, accreditation, and improvement of these methodologies, more than 40 thousand patients participated in the studies. The tests are carried out in accredited (CAP, CLIA, TÜV SÜD, etc.) laboratories which are equipped with modern equipment and where highly qualified personnel is working. All this ensures that the tests are accurate and safe, and the services provided meet the highest quality standards.

Liquid biopsy cancer tests

For healthy individuals. Early screening for those who want to evaluate the risk of oncological disease (solid tumors)

Patients participated in the validation study
0

For oncological patients. A comprehensive study of tumor and circulating tumor cells in patients for whom current treatment is ineffective.

Analyzed data points.
0

For patients in remission. The test allows us to predict cancer relapses or changes in tumor characteristics at an early stage.

Oncogenes analyzed in the ctDNA
0

Register for the test